Amgen (NASDAQ: AMGN) said the U.S. Food and Drug Administration approved an update to the prescribing information for Imdelltra (tarlatamab-dlle) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE